Literature DB >> 23118293

Interleukin 22, a potential therapeutic target for rheumatoid arthritis.

Qiang Xie, Shi-Cun Wang, Jun Li.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23118293     DOI： 10.3899/jrheum.120757

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  3 in total

Review 1.  Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.

Authors:  Patrizia Fasching; Martin Stradner; Winfried Graninger; Christian Dejaco; Johannes Fessler
Journal:  Molecules       Date:  2017-01-14       Impact factor: 4.411

2.  Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis.

Authors:  You Jung Ha; Eun-Jin Kang; Sang-Won Lee; Soo-Kon Lee; Yong-Beom Park; Jung-Soo Song; Sang Tae Choi
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

3.  Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients.

Authors:  Pablo R G Cardoso; Katherine A Matias; Andrea T Dantas; Claudia D L Marques; Michelly C Pereira; Angela L B P Duarte; Moacyr Jesus Barreto de Melo Rego; Ivan da Rocha Pitta; Maira Galdino da Rocha Pitta
Journal:  Open Rheumatol J       Date:  2018-09-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.